COVID-19 permanently changed how healthcare systems operate, fund innovation, and adopt technology. During the pandemic, telemedicine and digital triage tools surged out of necessity. In the post-COVID era, healthtech has matured. Startups now focus on solving structural problems such as clinician burnout, data fragmentation, diagnostic backlogs, and access gaps rather than offering standalone digital experiences.
Global healthtech funding rebounded strongly through 2024 and 2025. Venture capital firms increasingly backed startups that demonstrate measurable cost reduction, workflow efficiency, and clinical adoption. Artificial intelligence became the central driver of this shift, especially in documentation, diagnostics, patient engagement, and care coordination.
Below are ten healthtech startups that best represent post-COVID healthcare transformation, supported by recent funding data, valuations, and deployment scale. This list does not rank companies by size alone. It highlights momentum, real-world adoption, and strategic relevance in a post-pandemic healthcare system.
1. Abridge – AI documentation at health system scale
Abridge builds AI systems that convert clinician-patient conversations into structured medical notes in real time. After COVID, clinician burnout reached critical levels due to staff shortages and administrative overload. Health systems prioritized tools that directly reduce documentation time.
In February 2025, Abridge raised $250 million after completing a $150 million round in 2024. By early 2025, roughly 100 health systems had deployed its technology across outpatient and inpatient settings. Hospitals adopted Abridge not as an experimental AI tool but as core clinical infrastructure. The company represents one of the clearest examples of post-COVID AI delivering immediate operational value.
2. Nabla – From AI scribe to clinical workflow agent
Nabla started with AI-powered clinical documentation and expanded toward broader workflow automation. The company positions its product as a clinical copilot rather than a single-purpose scribe.
In mid-2025, Nabla closed a $70 million Series C round to accelerate development of agent-like AI systems that assist clinicians before, during, and after patient encounters. Health systems adopted Nabla to reduce cognitive load, standardize notes, and integrate AI directly into electronic health record workflows. The company reflects the post-COVID demand for AI that fits naturally into daily clinical practice.
3. Hippocratic AI – Patient-facing AI at massive scale
Hippocratic AI focuses on patient-facing AI agents rather than clinician tools. Its technology supports patient education, outreach, navigation, and follow-ups, especially for high-volume care programs.
The company raised $141 million in a Series B round in January 2025, followed by a $126 million Series C in November 2025 at a $3.5 billion valuation. Health systems and payers use Hippocratic AI to manage patient engagement at scale without expanding call centers or administrative staff. Post-COVID healthcare placed sustained pressure on care coordination, making this approach increasingly valuable.
4. Aidoc – Hospital AI platform and operating system
Aidoc initially gained recognition for AI-powered medical imaging analysis. In the post-COVID period, it evolved into a broader clinical AI platform that allows hospitals to deploy, monitor, and govern multiple AI models.
In July 2025, Aidoc raised $150 million to expand its foundation model strategy and enterprise hospital footprint. Hospitals now use Aidoc not just for diagnostics but also as infrastructure to manage AI safely and consistently. This shift mirrors how healthcare organizations moved from piloting isolated AI tools to managing AI portfolios at scale.
5. Innovaccer – Data and AI infrastructure for value-based care
Innovaccer operates at the data layer of healthcare, connecting fragmented clinical, claims, and operational datasets. Post-COVID care models rely heavily on population health management, analytics, and AI-driven insights.
In January 2025, Innovaccer raised $275 million in a Series F round at a reported valuation of approximately $3.2 billion. Health systems and payers use Innovaccer to support value-based contracts, quality reporting, and care management programs. The company addresses a core post-COVID reality: healthcare innovation fails without unified data.
6. Qure.ai – AI diagnostics with global reach
Qure.ai develops AI-based imaging tools for disease detection and triage, including tuberculosis, lung cancer, and stroke-related conditions. During COVID, screening programs stalled worldwide. Post-COVID systems needed scalable diagnostic support to address backlogs.
By 2025, Qure.ai had deployed its solutions in over 100 countries and secured 18 FDA clearances, including several approvals granted in 2024. Governments, hospitals, and public health agencies rely on Qure.ai to expand diagnostic capacity without proportional increases in radiologist staffing.
7. Dozee – Contactless monitoring beyond the ICU
Dozee provides contactless remote patient monitoring using AI-powered early warning systems. Hospitals expanded general ward monitoring after COVID highlighted the risks of late deterioration detection.
In March 2025, Dozee raised approximately $8.3 million through a mix of equity and debt financing. Clinical studies showed that its AI system could predict patient deterioration up to 16 hours in advance. Hospitals use Dozee to improve outcomes while reducing nurse workload, particularly in non-ICU settings.
8. Even Healthcare – Managed care reimagined
Even Healthcare combines insurance, care delivery, and owned hospital infrastructure into a membership-style model. Post-COVID consumers demanded simpler, faster, and more predictable healthcare experiences.
In January 2026, Even Healthcare raised $20 million to expand its managed-care hospital network. The company focuses on end-to-end control of patient experience, including financing, care coordination, and clinical delivery. This integrated approach reflects a broader post-COVID trend toward system-level redesign rather than isolated digital tools.
9. Maven Clinic – Women’s and family health at enterprise scale
Maven Clinic delivers virtual and hybrid care for women’s and family health, including fertility, pregnancy, postpartum, and pediatrics. Employers increasingly view these services as essential benefits rather than optional perks.
In October 2024, Maven raised $125 million in a Series F round, reaching a valuation of $1.7 billion. The company serves large employers and health plans globally. Post-COVID workforce priorities around retention and wellbeing strengthened Maven’s position as a category leader.
10. Headway – Fixing mental healthcare access through insurance
Mental health demand surged during COVID and remained elevated afterward. Headway addresses access by enabling therapists to accept insurance more easily through credentialing, scheduling, and billing support.
In July 2024, Headway raised $100 million in a Series D round at a $2.3 billion valuation. By reducing administrative friction, the company unlocked previously unavailable provider capacity. Post-COVID mental healthcare scaling depends as much on infrastructure as on clinical innovation, which Headway directly targets.
What defines post-COVID healthtech leadership
Post-COVID healthtech leaders share three defining traits. They reduce labor pressure through automation rather than adding complexity. They integrate into real clinical and financial workflows instead of operating as standalone apps. They scale across systems, regions, and care settings with measurable outcomes.
The pandemic accelerated digital adoption. The post-COVID era rewards startups that convert that adoption into durable healthcare infrastructure.
Also Read – Is Innovation Without Ethics Dangerous?